181 related articles for article (PubMed ID: 19280165)
1. [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].
Kowalzick L; Eickenscheidt L; Komar M; Schaarschmidt E
Hautarzt; 2009 Aug; 60(8):655-7. PubMed ID: 19280165
[TBL] [Abstract][Full Text] [Related]
2. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
[No Abstract] [Full Text] [Related]
3. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
4. Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy.
Pirmit S; Onsun N; Su O; Ozkaya DB
G Ital Dermatol Venereol; 2017 Apr; 152(2):126-131. PubMed ID: 28166613
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment.
Famenini S; Wu JJ
Cutis; 2013 Sep; 92(3):140-7. PubMed ID: 24153143
[TBL] [Abstract][Full Text] [Related]
6. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.
Kouklakis G; Efremidou EI; Pitiakoudis M; Liratzopoulos N; Polychronidis ACh
Drug Des Devel Ther; 2013; 7():195-9. PubMed ID: 23569358
[TBL] [Abstract][Full Text] [Related]
7. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
9. Malignant melanoma during treatment with fumaric acid esters - coincidence or treatment-related?
Barth D; Simon JC; Wetzig T
J Dtsch Dermatol Ges; 2011 Mar; 9(3):223-5. PubMed ID: 20678147
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.
Di Lernia V; Ricci C
J Dermatolog Treat; 2011 Aug; 22(4):229-32. PubMed ID: 20666674
[TBL] [Abstract][Full Text] [Related]
11. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab.
Mahé E; Descamps V; Grossin M; Fraitag S; Crickx B
Br J Dermatol; 2003 Jul; 149(1):170-3. PubMed ID: 12890213
[TBL] [Abstract][Full Text] [Related]
12. Melanoma occurrence under long-term etanercept treatment for psoriasis: a case report.
Atzori L; Pilloni L; Murgia S; Mugheddu C; Pau M; Rongioletti F
Dermatol Online J; 2016 Oct; 22(10):. PubMed ID: 28329597
[TBL] [Abstract][Full Text] [Related]
13. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.
Fulchiero GJ; Salvaggio H; Drabick JJ; Staveley-O'Carroll K; Billingsley EM; Marks JG; Helm KF
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S65-7. PubMed ID: 17434043
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
15. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
16. An overview of developing TNF-α targeted therapy for the treatment of psoriasis.
Campa M; Ryan C; Menter A
Expert Opin Investig Drugs; 2015; 24(10):1343-54. PubMed ID: 26289788
[TBL] [Abstract][Full Text] [Related]
17. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
18. Mycosis fungoides in the era of antitumour necrosis factor-α treatments.
Nikolaou V; Papadavid E; Economidi A; Marinos L; Moustou E; Karampidou K; Papadaki T; Stratigos A; Antoniou C
Br J Dermatol; 2015 Aug; 173(2):590-3. PubMed ID: 25639382
[No Abstract] [Full Text] [Related]
19. [Multiple basal cell carcinomas after etanercept treatment for psoriasis].
Maire C; Delesalle F; Carpentier O; Lequint P; Delaporte E; Thomas P
Ann Dermatol Venereol; 2009 Apr; 136(4):355-9. PubMed ID: 19361704
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
